Osimertinib (Tagrisso®) Adjuvant treatment stage IB-IIIA NSCLC. HTA ID: 21066

Assessment Status NCPE assessment ongoing
HTA ID 21066
Drug Osimertinib
Brand Tagrisso®
Indication or adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer whose tumour has epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
Assessment Process
Rapid review commissioned 20/12/2021
Rapid review completed 13/01/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/01/2022
Pre-submission consultation with Applicant 15/03/2022
Full submission received from Applicant 16/08/2022
Preliminary review sent to Applicant 27/01/2022
NCPE assessment re-commenced 13/03/2023